CurrentBlue Cross Blue Shield - South DakotaPolicy N/A

Circulating Tumor Cells (CTCs) for Cancer Management — Coverage Criteria

Customize your policy alerts

Sign up for all blue cross blue shield - south dakota policy alerts

Know when blue cross blue shield - south dakota releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs use of circulating tumor cell assays (e.g., CellSearch) for screening, prognosis, prediction of therapy response, and monitoring in individuals with cancer for Blue Cross Blue Shield - South Dakota members.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - South DakotaPolicy N/A

Circulating Tumor Cells (CTCs) for Cancer Management — Coverage Criteria

Customize your policy alerts

Sign up for all blue cross blue shield - south dakota policy alerts

Know when blue cross blue shield - south dakota releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyCirculating Tumor Cells (CTCs) for Cancer Management — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateMar 1, 2008

Last ReviewDec 1, 2025

Next Review DateDec 1, 2025

Key ActionWhen tissue biopsy is feasible, use standard tissue-based molecular characterization or imaging before considering CTC testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

investigationalcoverage stance

through Nov 2025literature update

Mar 2008original effective date

No direct benefitRCT evidence

ongoingongoing trials

Coverage Determination and Criteria

Investigational / Not medically necessary

Not covered except in research contexts; investigational for all indications

Investigational for all indications: The use of circulating tumor cells (CTCs) (e.g., CellSearch) is considered investigational for all indications in the management of cancer, including screening, prognosis, prediction of response to therapy, and monitoring the clinical course.

Evidence insufficient: clinical validity and clinical utility not established; published studies with clinical outcomes lacking; RCTs did not demonstrate benefit.

Selecting treatment in advanced cancer — Not supported

Not covered when ALL of the following apply:

Lack of clinical validity and utility: Clinical validity of each commercially available CTC test has not been established independently, and there is no direct evidence that selecting targeted treatment using CTCs improves net health outcomes compared with tumor tissue testing.

Trials are ongoing; evidence insufficient to demonstrate test performance for currently available CTC tests.

Comparator available: A standard tissue biopsy for molecular characterization is feasible and available as the appropriate comparator for informing targeted treatment selection.

When biopsy is possible, tissue molecular characterization is the preferred method.

No demonstrated outcome benefit: No published studies demonstrate that management guided by CTC results leads to improved overall survival or other net health outcomes compared with standard care.

Published studies reporting clinical outcomes and clinical utility are lacking.

Monitoring treatment response or detecting relapse — Not supported

Not covered when ALL of the following apply for monitoring or surveillance purposes:

Monitoring or surveillance without validated management pathway: There is no evidence-based management pathway demonstrating that using CTCs to trigger early treatment before clinical relapse improves outcomes.

No trials identified demonstrating benefit of treatment before relapse based on changes in CTCs; chain of evidence lacking.

Clinical validity not established per test: The clinical validity of each commercially available CTC assay has not been established; associations with prognosis do not alone establish clinical utility for monitoring.

Systematic reviews report prognostic associations, but per-test validation is lacking.

Randomized trial evidence negative for therapy change: Randomized trial evidence did not show improved overall survival when treatment was changed based on persistently elevated CTCs (e.g., SWOG S0500), so CTC-guided early intervention is not supported.

RCT found prognostic value but no survival benefit from therapy change based on CTCs.

Overall coverage determination

Coverage stance based on evidence summarized in this section

Primary rationale: There is insufficient evidence that using CTC tests to monitor treatment response or to guide changes in therapy improves net health outcomes; clinical validity must be established for each commercially available test and such data are lacking.

SWOG S0500 and other evidence show prognostic associations but do not demonstrate clinical benefit from CTC-guided management.

Policy conclusion: CTC testing is considered investigational and not medically necessary for selection of targeted therapy, monitoring treatment response, predicting relapse, screening, or prognosis in individuals with cancer.

Evidence insufficient to determine improvement in net health outcome.

This evidence review specifically excludes liquid biopsy tests based on circulating tumor DNA (ctDNA). For coverage and prior-authorization rules related to ctDNA assays, refer to the Molecular Testing Utilization Management Program rather than this CTC policy.

The clinical validity of each commercially available CTC test must be established independently before coverage can be considered. Tests for which per-test clinical validity has not been demonstrated are excluded from coverage.

Society guidance informs exclusions: the 2022 ASCO guideline states there are insufficient data to recommend routine use of CTCs to monitor response in metastatic breast cancer and recommends against using CTC testing to guide adjuvant therapy decisions in certain early-stage breast cancer subgroups. NCCN tumor‑specific guidelines do not incorporate routine CTC use in management for the tumor types reviewed.

Some sections of the source document provide coding and assay descriptions but do not define explicit clinical coverage criteria or medical‑necessity rules for particular indications; those sections focus on CPT/HCPCS and proprietary assay codes rather than test‑use criteria.

Based on available evidence, CTC testing is considered investigational and not medically necessary for selecting targeted treatment, monitoring treatment response, predicting relapse, screening, prognosis, or routine surveillance across cancer indications. The evidence is insufficient to conclude that CTC use improves net health outcomes.

Using CTC test results to select targeted systemic therapies or to initiate therapy earlier than clinical progression is not medically necessary when clinical validity for the specific assay is unestablished and randomized evidence demonstrating improved outcomes is lacking.

Currently available CTC assays are not supported by evidence to guide treatment changes. Randomized trial data (for example, SWOG S0500/Smerage et al.) showed prognostic information but did not demonstrate that changing therapy based on CTC results improved progression‑free or overall survival.

Placeholder: certain document sections enumerate codes and assay names (CPT/HCPCS/proprietary codes) and do not specify additional clinical items or rules; see the coding tables for details.

Coding and Billing Codes

Coding table referencedmixed

No codes listed

CTC enumeration CPT CodesCPT

86152

Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood)

Referenced CPT CodesCPT

86152

Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood)

Assay-specific HCPCS / Proprietary CodesHCPCS | Proprietary

86153	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood); physician interpretation and report, when required
0091U	Cell enumeration using immunologic selection and identification in fluid specimen; algorithm for presence of adenoma or cancer (FirstSight CRC / CellMax Life) — reported as positive/negative
0337U	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm for presence of adenoma or cancer; physician interpretation and report (FirstSight CRC, CellMax Life)
0338U	Circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells — CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Test
0490U	CELLSEARCH® HER2 Circulating Tumor Cell (CTC-HER2) Test
0491U	CELLSEARCH® Circulating Melanoma Cell (CMC) Test
0492U	CELLSEARCH® ER Circulating Tumor Cell (CTC-ER) Test

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Benefit verification and prior approval note

Benefit determinations are based on the member's contract and may vary by plan. Verify member benefits and coverage before ordering testing. Prior approval is not applicable for this policy, but refer to the Molecular Testing Utilization Management Program for Wellmark prior approval requirements and lab management guidelines related to molecular testing.

Verify member benefits and any applicable prior authorization per contract
Refer to Molecular Testing Utilization Management Program for molecular testing prior approval rules

Prior Authorization

Prior Authorization Required / Review Likely

Prior authorization may be required per the payer's molecular testing management program. Even when prior approval is noted as not applicable in this policy header, requests for CTC testing may be subject to utilization management review and prior authorization under the payer's Laboratory/Molecular Testing programs.

Check Molecular Testing Utilization Management Program for PA requirements

Background and Rationale

Circulating tumor cells (CTCs) are tumor cells shed from a primary or metastatic site into the peripheral blood. CTCs are commonly detected using epithelial surface markers (for example, EpCAM and cytokeratins), and they typically have a short circulating half‑life on the order of 1–2 hours.

Definitions and Test Descriptions

inv-34: Circulating tumor cell (CTC) assay — key characteristics

Enrichment stepCTC assays typically begin with an enrichment step that increases CTC concentration by biologic properties (protein marker expression such as EpCAM) or physical properties (size, density, charge)

Detection methodsAfter enrichment, CTCs are detected using immunologic, molecular, or functional assays

Short half-lifeCTCs have a short bloodstream half-life (about 1–2 hours), requiring sensitive enrichment/detection methods

Common markersMost assays detect CTCs using epithelial surface markers such as EpCAM and cytokeratins

Primary purposePrimary reason for detecting CTCs is prognostic through quantification of circulating levels

inv-35: Scope exclusion: ctDNA

Intended Use by Therapy Line

mixed

Line-of-therapy context: CTC testing may be considered only in the context of advanced cancer where treatment selection depends on tumor molecular characterization or when tissue biopsy is not feasible; however, such use remains investigational because clinical validity and utility are unestablished.

When biopsy and tumor tissue testing are feasible, tissue molecular characterization should be used prior to considering CTC testing.

Test Characteristics and Biomarker Reporting

inv-41: CTC presence/characterization — biomarker requirement notes

Required marker fieldCTC presence/characterization may be required when selecting targeted therapy if tissue biopsy is unavailable; clinical validity must be established for the specific test

ComparatorWhen biopsy is feasible, tumor tissue molecular characterization is the comparator; documentation should support biopsy infeasibility if CTCs are used instead

Evidence limitationClinical validity of each commercially available CTC test has not been established to date

inv-42: CTC enumeration / characterization — biomarker reporting requirements

Reporting elementsLaboratory reports should include CTC enumeration and any required physician interpretation/report that matches the specific assay and billed code

Characterization details

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyCirculating Tumor Cells (CTCs) for Cancer Management — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateMar 1, 2008

Last ReviewDec 1, 2025

Next Review DateDec 1, 2025

Key ActionWhen tissue biopsy is feasible, use standard tissue-based molecular characterization or imaging before considering CTC testing.

SourceLink

On This Page

Prior authorization may be required due to lack of established clinical validity/utility

Denial Risk

Investigational service denial risk

CTC assays are considered investigational for all indications in the management of cancer. Claims for investigational services may be denied. Providers should expect denials when submitting claims for CTC testing unless coverage criteria are explicitly met under the member's contract.

Investigational service; claims may be denied
Specify clinical indication and supporting documentation when submitting requests

Denial Risk

Lack of demonstrated clinical validity/utility

Clinical validity and clinical utility for each commercially available CTC test have not been established. Requests may be denied when evidence of clinical validity for the specific assay is lacking or when tests are used to guide therapy decisions without supportive trial evidence.

Lack of demonstrated clinical validity/utility may trigger denial
Clinical validity must be established for the specific commercially available assay

Step Therapy

Step-therapy not supported by evidence

Using CTC results to guide changes in therapy (step changes or switching regimens) is not supported by evidence of improved outcomes (e.g., SWOG S0500). Claims may be denied when CTC testing is used as the basis for altering treatment without clear, validated clinical utility.

CTC-driven therapy-switching strategies lack evidence of improved survival
Denial risk when CTCs are used to guide therapy changes

Billing Rule

Coding and reporting requirement

Report the appropriate CPT, HCPCS, revenue, and ICD diagnosis codes that correspond to the specific assay performed. Include physician interpretation and report when required by the CPT/HCPCS descriptor. Failure to use correct coding or to include required documentation may result in claim denials.

Use CPT 86152 for cell enumeration when appropriate
Use assay-specific CPT/HCPCS (eg, 86153 / Q- or U-codes listed) where applicable
Include physician interpretation and report when required
Failure to use appropriate coding may trigger claim denials

Documentation Required

Coding-related documentation and comparator requirements

Lab reports should include cell enumeration results and the interpreting physician's report when indicated; documentation should state comparators used (e.g., tissue biopsy or imaging) and reasons when tissue biopsy is not feasible. Maintain records showing why tissue-based testing or imaging was not performed if CTC testing is submitted as an alternative.

Include enumeration and physician interpretation matching the assay
Document comparator testing (tissue biopsy or imaging) or reasons biopsy was not feasible

Scope exclusionThis evidence review excludes circulating tumor DNA (ctDNA) liquid biopsies; see the Molecular Testing Utilization Management Program

Separate policyctDNA liquid biopsy testing is addressed under the Molecular Testing Utilization Management Program

Not evaluated hereFindings, validity, and coverage determinations for ctDNA are outside the scope of this CTC policy

inv-36: CTC definition

Short labelCirculating Tumor Cells (CTCs)

DefinitionTumor-derived cells shed into peripheral blood from primary or metastatic sites detected to inform prognosis, treatment selection, or monitoring

Clinical contextsProposed uses include screening, prognosis, predicting therapy response, and monitoring disease course

inv-37: Circulating tumor cells (CTCs) — enumeration and CPT 86152

ModalityTumor-derived cells in blood identified and enumerated via immunologic selection and identification methods

CPT codeCPT 86152 describes cell enumeration using immunologic selection and identification in a fluid specimen (e.g., CTCs in blood)

ReportingEnumeration results are reported as cell counts and may be accompanied by physician interpretation when applicable

inv-38: Circulating tumor cell test / Cell enumeration assay

Core definitionCell enumeration using immunologic selection and identification in a fluid specimen (e.g., circulating tumor cells in blood)

Optional componentsMay include physician interpretation/report and biomarker quantification (e.g., HER2, ER, PD-L1) depending on the assay

Assay examplesCommercial assays include CellSearch® and other vendor-specific tests that pair enumeration with biomarker algorithms

inv-39: Circulating multiple myeloma cell (CMMC) test

Test descriptionCirculating multiple myeloma cell (CMMC) test: circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration in peripheral blood

Biomarkers usedDifferential expression of CD138, CD38, D19, and CD45 protein biomarkers are used to identify and enumerate plasma cells

CPT/Proprietary codeAssay-specific codes describe physician interpretation and reporting when required (e.g., 0338U for CELLSEARCH® CMMC Test)

Characterization may include biomarker quantification (e.g., HER2, ER, PD-L1) and morphological description depending on the assay

Coding linkageReported enumeration/characterization must correspond to the appropriate CPT/HCPCS/proprietary code for the assay performed

inv-43: HER2 — biomarker field referenced for CTC characterization

BiomarkerHER2 quantified on CTCs using specific assays (e.g., CELLSEARCH® HER2 CTC test)

PurposeQuantification of HER2-expressing CTCs is intended to identify HER2 protein–expressing tumor cells in peripheral blood

CodingCELLSEARCH® HER2 test corresponds to proprietary code 0490U (and may be billed with related CPT/HCPCS codes)

inv-44: ER — biomarker field referenced for CTC characterization

BiomarkerEstrogen receptor (ER) expression can be quantified on circulating tumor cells (CTC-ER assays)

Assay exampleCELLSEARCH® ER Circulating Tumor Cell (CTC-ER) Test is described in coding guidance (proprietary code 0492U)

ReportingER quantification on CTCs is an optional characterization component reported with the assay-specific code and interpretation when required

inv-45: PD-L1 — biomarker field referenced for CTC characterization

BiomarkerPD-L1 expression may be quantified on circulating tumor cells as part of some assays (CTC-PD-L1)

Assay exampleCELLSEARCH® PD-L1-related CTC testing is described in coding listings as quantifying PD-L1–expressing cells in peripheral blood

Clinical contextPD-L1 quantification on CTCs is an optional characterization component; clinical validity/utility for guiding therapy is not established